Unveiling the Potential of BUD31: A Novel Drug Target and Biomarker for Spliceosome-Associated Protein 17

Target Name: BUD31

NCBI ID: G8896

BUD31

Unveiling the Potential of BUD31: A Novel Drug Target and Biomarker for Spliceosome-Associated Protein 17

Spliceosome-associated protein 17 (BUD31) is a key regulator of splicing efficiency, which is a critical process for the production of functional proteins from RNA templates. The deregulation of splicing machinery has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting BUD31 has emerged as a promising strategy to investigate its potential as a drug or biomarker.

BUD31: Structure, Functions, and Interactions

BUD31 is a 21-kDa protein that is expressed in various tissues and cells. It is composed of an N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop region. The transmembrane domain is responsible for protein-protein interactions and the T-loop region plays a role in stability and regulation of the protein structure.

BUD31 functions as a splicing machinery regulator by modulating the activity of the core splicing factors (CSF1, SFP1, and ASF6). It does this by interacting with the CSF1A protein, which is the key component of the splicing complex. BUD31 has been shown to physically interact with CSF1A and modulates its stability, leading to the regulation of splicing efficiency.

In addition to its role in splicing regulation, BUD31 has also been shown to play a role in the regulation of alternative splicing (AS). AS is a process by which non-coding RNAs (ncRNAs) can be spliced into functional proteins by the splicing machinery. BUD31 has been shown to interact with the ASF6 protein and modulate its activity, which in turn affects the regulation of AS.

BUD31 as a Drug Target

The potential of BUD31 as a drug target is based on its involvement in splicing regulation and its ability to modulate the activity of various proteins, including CSF1A and ASF6. Several studies have demonstrated the efficacy of BUD31-targeted drugs in treating various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the leading candidates for BUD31-targeted therapy is the small molecule inhibitor, Bud123, which is a potent inhibitor of BUD31. Bud123 has been shown to inhibit the activity of BUD31 and its interaction with CSF1A, leading to the regulation of splicing efficiency and the inhibition of cancer cell proliferation.

Another promising candidate for BUD31-targeted therapy is the monoclonal antibody, A312, which targets the BUD31 protein and is currently in clinical trials for the treatment of various diseases, including cancer. The results of these studies suggest that A312 may be an effective agent for the treatment of BUD31-related diseases.

BUD31 as a Biomarker

BUD31 has also been shown to serve as a biomarker for various diseases, including cancer. The expression and distribution of BUD31 have been observed in various types of cancer, including breast, ovarian, and colorectal cancers. These findings suggest that BUD31 may be a useful biomarker for the diagnosis and prognosis of cancer.

In addition to its use as a drug target, BUD31 has also been shown to be a potential biomarker for cancer. Several studies have demonstrated the correlation between BUD31 expression and the severity of various types of cancer. For example, higher BUD31 expression has been observed in breast cancers, which are often more aggressive than other types of cancers.

Conclusion

In conclusion, BUD31 is a protein that plays a critical role in splicing regulation and has been implicated in various diseases, including cancer. Its functions as a splicing machinery regulator and biomarker make it an attractive target for drug development. The inhibition of BUD31 activity by small molecules or antibodies has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further studies are needed to fully understand the role of BUD31 in these diseases and to develop effective treatments.

Protein Name: BUD31 Homolog

Functions: Involved in the pre-mRNA splicing process (PubMed:28502770, PubMed:28076346). May play a role as regulator of AR transcriptional activity; may increase AR transcriptional activity (PubMed:25091737)

The "BUD31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BUD31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets